drugset / Trial / NCT00733785

PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers

NCT00733785

Phase 1 Completed 60 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelTreatment

Summary

The present pharmacokinetic study is designed to further characterise the pharmacokinetics of the RSG XR formulation and aims to assess dose proportionality, strength equivalence, the food effect and the pharmacokinetics after repeat dosing.

Timeline

Start
2008-08-13
Primary completion
2008-11-28
Completion
2008-11-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosiglitazone Small molecule 2 mg
Subject Rosiglitazone Small molecule 4 mg
Subject Rosiglitazone Small molecule 8 mg

Indications